Dividends & Buybacks ·
Clearmind Medicine consolidates shares at a ratio of 1-for-8, reducing outstanding count to approximately 507,404
CMNDClearmind Medicine Inc.
Clearmind Medicine Inc. announced a reverse stock split of its common shares at a ratio of 1-for-8, consolidating eight pre-split shares into one post-split share. The transaction will reduce the number of issued and outstanding ordinary shares from 4,059,227 to approximately 507,404, with no fractional shares issued; any fractions are rounded up to the nearest whole share. Proportionate adjustments apply to the exercise prices and share counts of all outstanding options and warrants. The new CUSIP number is 185053709, and trading on the Nasdaq Capital Market under the split terms begins on October 5, 2026. Clearmind Medicine Inc. operates in the biotechnology industry, focusing on the development of psychedelic-based therapeutics for mental health disorders.